Clinical development of neridronate: potential for new applications

Gatti, Davide; Rossini, Maurizio; Viapiana, Ombretta; Idolazzi, Luca; Adami, Silvano

doi:10.2147/tcrm.s35788

Cited by 21 publications

(7 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…30 No cases of jaw osteonecrosis have been reported in patients treated with neridronate, even after longer periods of treatment. 63 Some patients develop hypocalcaemia, but symptomatic hypocalcaemia has not been reported. In one case report, an 84-year-old woman developed acute pseudogout after a single intravenous injection of neridronate.…”

Section: Safetymentioning

confidence: 99%

Neridronate: From Experimental Data to Clinical Use

Corrado

Colìa

Cantatore

2017

Clinical Medicine Insights: Therapeutics

View full text Add to dashboard Cite

Neridronate is an amino-bisphosphonate that has been officially approved as a treatment for osteogenesis imperfecta, Paget’s disease of bone and type I complex regional pain syndrome in Italy. Neridronate is administered either intravenously or intramuscularly; thus, it represents a valid option for both cases with contraindications to the use of oral bisphosphonates and cases with contraindications or an inability to receive an intravenous administration of these drugs. Furthermore, although the official authorized use of neridronate is limited to only 3 bone diseases, many experimental and clinical studies support the rationale for its use and provide evidence of its effectiveness in other pathologic bone conditions that are characterized by altered bone remodelling.

show abstract

Section: Safetymentioning

confidence: 99%

Neridronate: From Experimental Data to Clinical Use

Corrado

Colìa

Cantatore

2017

Clinical Medicine Insights: Therapeutics

View full text Add to dashboard Cite

show abstract

“…Inhibition of this pathway prevents proteins from acting at the correct location in the cell. This leads to changes in many cellular processes including cytoskeletal organization, vesicular trafficking and apoptosis [28,[31][32][33][34].…”

Section: Mechanism Of Actionmentioning

confidence: 99%

A Review Into the Effects of Pamidronic Acid and Zoledronic Acid on the Oral Mucosa in Medication-Related Osteonecrosis of the Jaw

Bullock

Miller

McKechnie

et al. 2022

Front. Oral. Health

View full text Add to dashboard Cite

Medication-related osteonecrosis of the jaw (MRONJ) is a growing problem without an effective treatment, presenting as necrotic bone sections exposed via lesions in the overlying soft tissue. There is currently a lack of clarity on how the factors involved in MRONJ development and progression contribute to disease prognosis and outcomes. Bisphosphonates (BPs), the most common cause of MRONJ, affect bone remodeling, angiogenesis, infection, inflammation and soft tissue toxicity, all of which contribute to MRONJ development. This article reviews the cellular mechanisms through which BPs contribute to MRONJ pathology, with a focus on the effects on cells of the oral mucosa. BPs have been shown to reduce cell viability, reduce proliferation, and increase apoptosis in oral keratinocytes and fibroblasts. BPs have also been demonstrated to reduce epithelial thickness and prevent epithelial formation in three-dimensional tissue engineered models of the oral mucosa. This combination of factors demonstrates how BPs lead to the reduced wound healing seen in MRONJ and begins to uncover the mechanisms through which these effects occur. The evidence presented here supports identification of targets which can be used to develop novel treatment strategies to promote soft tissue wound healing and restore mucosal coverage of exposed bone in MRONJ.

show abstract

“…В отличие от других бисфосфонатов неридронат может назначаться как внутривенно, так и внутримышечно [39], разрешен к применению у детей с грудного возраста.…”

Section: педиатрическая фармакологияunclassified